SASB Index
This report outlines how our existing disclosures align with the recommended metrics for the SASB Biotechnology & Pharmaceuticals standards. All data is for the year ended December 31, 2022, unless otherwise noted.
Safety of Clinical Trial Participants
SASB Code
|
Accounting Metric
|
Response
|
|---|---|---|
|
HC-BP-210a.1
|
Accounting Metric:
Discussion, by world region, of management process for ensuring quality and patient safety during clinical trials
| Response: |
|
HC-BP-210a.2
|
Accounting Metric:
Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in: (1) Voluntary Action Indicated (VAI) and (2) Official Action Indicated (OAI)
|
Response:
Not Disclosing
|
|
HC-BP-210a.3
|
Accounting Metric:
Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries
|
Response:
Not Disclosing
|
Access to Medicines
SASB Code
|
Accounting Metric
|
Response
|
|---|---|---|
|
HC-BP-240a.1
|
Accounting Metric:
Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index
| Response: |
|
HC-BP-240a.2
|
Accounting Metric:
List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)
|
Response:
Lilly does not have products on the PQP
|
Affordability & Pricing
SASB Code
|
Accounting Metric
|
Response
|
|---|---|---|
|
HC-BP-240b.1
|
Accounting Metric:
Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/or provisions to delay bringing an authorized generic product to market for a defined time period
|
Response:
Zero. Lilly does not pay for delays.
|
|
HC-BP-240b.2
|
Accounting Metric:
Percentage change in: (1) average list price and (2) average net price across U.S. product portfolio compared to previous year
| Response: |
|
HC-BP-240b.3
|
Accounting Metric:
Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous year
|
Response:
Not Disclosing
|
Drug Safety
SASB Code
|
Accounting Metric
|
Response
|
|---|---|---|
|
HC-BP-250a.1
|
Accounting Metric:
List of products listed in the Food and Drug Administration’s (FDA) MedWatch Safety Alerts for Human Medical Products database
| Response: |
|
HC-BP-250a.2
|
Accounting Metric:
Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System
| Response: |
|
HC-BP-250a.3
|
Accounting Metric:
Number of recalls issued, total units recalled
| Response: |
|
HC-BP-250a.4
|
Accounting Metric:
Total amount of product accepted for takeback, reuse, or disposal
|
Response:
Not Disclosing
|
|
HC-BP-250a.5
|
Accounting Metric:
Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type
|
Response:
Not Disclosing
|
Conterfeit Drugs
SASB Code
|
Accounting Metric
|
Response
|
|---|---|---|
|
HC-BP-260a.1
|
Accounting Metric:
Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting
| Response: |
|
HC-BP-260a.2
|
Accounting Metric:
Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit products
| Response: |
|
HC-BP-260a.3
|
Accounting Metric:
Number of actions that led to raids, seizure, arrests, and/or filing of criminal charges related to counterfeit products
|
Response:
Not Disclosing
|
Ethical Marketing
SASB Code
|
Accounting Metric
|
Response
|
|---|---|---|
|
HC-BP-270a.1
|
Accounting Metric:
Total amount of monetary losses as a result of legal proceedings associated with false marketing claims
|
Response:
Not Disclosing
|
|
HC-BP-270a.2
|
Accounting Metric:
Description of code of ethics governing promotion of off-label use of products
| Response: |
Employee Recruitment, Development & Retention
SASB Code
|
Accounting Metric
|
Response
|
|---|---|---|
|
HC-BP-330a.1
|
Accounting Metric:
Discussion of talent recruitment and retention efforts for scientists and research and development personnel
| Response: |
|
HC-BP-330a.2
|
Accounting Metric:
(1) Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) mid level managers, (c) professionals, and (d) all others
| Response: |
Supply Chain Management
SASB Code
|
Accounting Metric
|
Response
|
|---|---|---|
|
HC-BP-430a.1
|
Accounting Metric:
Percentage of (1) entity's facilities and (2) Tier I suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent third party audit programs for integrity of supply chain and ingredients
| Response: |
Business Ethics
SASB Code
|
Accounting Metric
|
Response
|
|---|---|---|
|
HC-BP-510a.1
|
Accounting Metric:
Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery
|
Response:
Not Disclosing
|
|
HC-BP-510a.2
|
Accounting Metric:
Description of code of ethics governing interactions with healthcare professionals
| Response: |
Activity Metrics
SASB Code
|
Activity Metric
|
Response
|
|---|---|---|
|
HC-BP-000.A
|
Activity Metric:
Number of patients treated
| Response: |
|
HC-BP-000.B
|
Activity Metric:
Number of drugs (1) in portfolio and (2) in research and development (Phases 1-3)
| Response: |
See important information about our ESG report.